Loading
A phase 1/2 trial of 177Lu-BetaBart in prostate cancer, colorectal cancer, non-small-cell lung cancer, ovarian cancer, cervical cancer and endometrial cancer, run by Radiopharm Theranostics, Ltd, now recruiting.
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07189871 by Radiopharm Theranostics, Ltd, with 61 participants planned, started 2026-02-23 and due to reach its primary completion in 2027-12. Interventions recorded: 177Lu-BetaBart.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Medpace, Radiopharm Theranostics and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Radiopharm Theranostics, Prostate cancer and the tag pipeline.
Shares Medpace, Ovarian cancer, Colorectal cancer and the tag pipeline.
Shares Medpace, Ovarian cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Medpace and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/